ReviewCurrent urology reports2007
Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma.
Review in Current urology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Urological cancer: towards rational post-nephrectomy follow-up guidelines in RCC.Nature reviews. Clinical oncology · 2015Article
- Transthoracic echo: A sensitive tool for detecting cardiac extension of renal cell carcinoma?World journal of clinical cases · 2014Article
- Metastatic renal clear-cell carcinoma to the gallbladder: A radiologist's perspective.Radiology case reports · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there have been multiple advances in imaging technologies that have improved the surveillance for recurrence of neoplasms. Multidetector row CT and dynamic contrast enhanced MRI now provide excellent anatomic detail and are beginning to show functional detail as the rapid capture of images following contrast administration improves. Positron emission tomography is emerging as a useful tool in evaluating patients with suspected metastatic disease to the abdomen and bone, particularly when combined with CT. The role of ultrasound in the surveillance of renal cell carcinoma is yet unclear, but its role may be expanding with use of newly developed contrast drugs. Herein we review the relevance of these modalities to the follow-up of patients with renal cell carcinoma.
Indexed as
Identifiers
17239315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.